Careismatic Brands Launches “19 Days of Gratitude” Global Campaign to Support Nurses and the DAISY Foundation
24.9.2020 16:00:00 EEST | Business Wire | Press release
Careismatic Brands, the world’s largest designer and manufacturer of medical apparel, today announced the launch of a global tribute and charitable fundraising campaign, “19 Days of Gratitude,” spotlighting the heroism of nurses as they continue to battle COVID-19 on the front lines. Launching in a year that the World Health Organization has deemed “The International Year of The Nurse and Midwife,” and timed to the 200th anniversary of Florence Nightingale’s birth, the new campaign will celebrate nurses by revealing 19 stories that showcase frontline nurses from around the world over 19 consecutive days. The campaign will debut on careismatic.com/TributeToCourage and across Careismatic’s various social and digital channels, to celebrate the nursing community and raise money for the DAISY (Diseases Attacking the Immune System) Foundation, a worldwide organization recognizing the incredible work and sacrifice of nurses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005263/en/
Medical apparel manufacturer, Careismatic Brands, launches global campaign to pay tribute to nurses and raise funds for the DAISY Foundation (Graphic: Business Wire)
The campaign will kick off with a powerful tribute video “In The Year of The Nurse – A Tribute to Courage,” shot and produced by Hollywood creative agency Mob Scene. The video features a reimagined recording of George Harrison’s classic song, “Give Me Love (Give Me Peace on Earth)” from Grammy Award-winning music producer Rob Cavallo (former Chairman of Warner Bros. Records, whose accolades include 1988 Producer of the Year; 2005 Record of the Year for Green Day’s Boulevard of Broken Dreams; and selling in excess of 160 million records worldwide). Cavallo’s version of “Give Me Love (Give Me Peace on Earth)” features children singing from home and is designed to recognize and uplift health care professionals during this pandemic.
“Health care professionals are selfless people who are putting themselves on the line to save people’s lives during this COVID-19 crisis and this campaign is a tribute to them,” said Michael Singer, CEO of Careismatic Brands. “Our mission at Careismatic Brands is to champion the people behind the scrubs, and we are honored to share this very meaningful tribute as a way to thank the people who have given so much hope and professional care – at much personal risk – to so many COVID patients during these extraordinary times.”
Cavallo rerecorded the song during the middle of the pandemic’s stay-at-home mandate, so he was forced to creatively develop a process of overlaying each individual singer’s track while working remotely with engineers and musicians.
“We kept coming back to Give Me Love’s lyrics, which are incredibly meaningful and exactly what people need to hear during these unprecedented times,” Cavallo said. “George Harrison found the song to be profoundly moving and described it as a prayer and personal statement between him, the Lord and whoever likes it. If our version of this beautiful classic can brighten one nurse’s day after the incredible sacrifice they are making, it is all worth it.”
The video ends by encouraging viewers to donate to the DAISY Foundation. The fundraising effort will support their traditional programs as well as a new initiative awarding nurses grants to advance health equity in underserved communities.
“Careismatic Brands has been a longtime supporter of the DAISY Foundation and our mission to award and celebrate nurses as the unsung heroes providing quality health care,” said Bonnie Barnes, Co-Founder of the DAISY Foundation. “When we first saw the ‘Tribute to Courage’ video and heard its score with the plea for love and hope, we were immediately struck by its power and ability to provide a much-needed lift to nurses during this incredibly difficult time. We are thrilled that Careismatic Brands will be bringing this important tribute to nurses and offering a fundraising opportunity to the public,” Barnes continued. “Donations will fund nurse recognition as well as important research done by nurses to ensure that all people, no matter their race or economic situation, receive high-quality health care.”
Careismatic Brands’ “19 Days of Gratitude” campaign comes on the heels of the company’s $1 million donation of its Cherokee Uniforms and Dickies Medical branded scrubs to health care workers. The company delivered scrubs to more than 200 hospitals, in areas most impacted by the virus, to help health care workers lacking personal protective equipment get the apparel they needed to either change or even dispose of their scrubs throughout the day to avoid viral spread.
For more information on how to access the campaign, music video, 19 stories from nurses around the globe and to donate, please visit careismatic.com/TributeToCourage.
ABOUT CAREISMATIC BRANDS
Careismatic Brands, Inc. (formerly Strategic Partners, Inc.) is the global leader in medical apparel with a distribution footprint in more than 70 countries, and a deep portfolio of top-selling medical apparel, footwear and accessories brands such as Cherokee Uniforms, Dickies Medical, heartsoul, Infinity by Cherokee, ScrubStar, Tooniforms and Anywear. Plus innovative and game-changing wellbeing brands such as Certainty SmartBoost, an antimicrobial laundry additive that works alongside regular detergent to protect fabrics. Careismatic Brands’ portfolio of deeply trusted brands delivers best-in-class products and unparalleled service to distribution partners and consumers.
In addition to being the marketshare leader in medical apparel, Careismatic Brands is a manufacturer/distributor of school uniforms by Classroom, corporate identity uniforms, adaptive clothing by Silverts, medical instruments and accessories. The company takes great care to understand and provide products that champion the people wearing uniforms who serve and care for others. For more information on Careismatic Brands, visit www.careismatic.com and follow us on Facebook and Instagram.
ABOUT DAISY
The DAISY Foundation™ is the leading international organization for nursing recognition. It was created in 1999 by the family of J. Patrick Barnes, in memory of the extraordinary nursing care they experienced when he was in the hospital for 2 months with an auto-immune disease. (DAISY stands for Diseases Attacking the Immune SYstem). His family’s drive to say “thank you” to nurses for the compassionate and skillful care they provide every day – The DAISY Award® for Extraordinary Nurses – has grown to become a highly respected and international nurse recognition program. It provides unique and meaningful recognition that benefits nurses and the organizations where they work.
Today, over 4,500 healthcare organizations and schools of nursing in 29 countries are committed to honoring their nurses with The DAISY Award. Over 1.8 million nurses have been nominated by their patients, families and colleagues, and over 144,000 awards have been granted.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005263/en/
Contact information
Sara Rosales
Careismatic Brands
srosales@strategicpartners.net
310/413-2413 (mobile)
Rachel Rogers
The Acceleration
rachel.rogers@theacceleration.com
310/770-4917 (mobile)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
